HAVCR2 and acute myeloid leukemia: Nowadays, it seems essential more than ever to perform in-vivo, preclinical, and clinical studies in the field of using combinational therapies that target both immunological and metabolic pathways, for example, TIM-3 and glutamine metabolism pathway in hematological malignancies such as AML.